13F-HR/A filed by Royalty Pharma Sub-Manager, LLC
Royalty Pharma Sub-Manager, LLC filed this 13F-HR/A for the quarter ended 2025-12-31, filed 2026-08-21, with 4 holding rows worth $171,312,250.
- Accession
- 0002081668-26-000015
- Filer
- CIK 2081668
- Filed
- 2026-08-21
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q4 2025
A holdings report, amendment of type restatement, 4 entries on the cover page, a total value of $171,312,250 stated on the cover page (in dollars after the unit check, H1), rows summing to $171,312,250 with VALUE read as dollars as filed, 13F file number 028-26787. The quarter's positions are built on this report. The resolved quarter.
Other managers
- included managerRoyalty Pharma Manager, LLC
- included managerRoyalty Pharma plc
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| CYTOKINETICS INC | 23282W605 | COM NEW | 980,392 | $62,294,108 | dollars as filed | |
| ZENAS BIOPHARMA INC COM | 98937L105 | Stock | 1,263,150 | $45,864,977 | dollars as filed | |
| BIOHAVEN LTD | G1110E107 | COM | 2,936,507 | $33,153,164 | dollars as filed | |
| BIOCRYST PHARMACEUTICALS INC COM | 09058V103 | Stock | 3,846,154 | $30,000,001 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0002081668-26-000003 | superseded | 2026-04-01 | acceptance time not in the bulk data set | |
| 13F-HR/A 0002081668-26-000015 | this filing | 2026-08-21 | acceptance time not in the bulk data set |